Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EYA2 | O00167 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30960193 | 1.00 | KDM4E (0.47) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL29892650 | 0.98 | KDM4E (0.48) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL2349945 | 0.98 | KDM4E (0.48) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL12453251 | 0.93 | KDM4E (0.46) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL22139380 | 0.91 | KDM4E (0.39) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL23568184 | 0.91 | KDM4E (0.50) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL2310414 | 0.89 | KDM4E (0.55) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL30538868 | 0.89 | KDM4E (0.55) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL26966749 | 0.89 | KDM4E (0.42) | KDM4ETDP1ALOX15TSHRACMSD | |
| SCHEMBL26966752 | 0.89 | BLM (0.46) | KDM4ETDP1ALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-28 | — | — | US | disclosed |
| US-11395857-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-07-26 | — | — | US | disclosed |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20220040340-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-02-10 | — | — | US | disclosed |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-12-30 | — | — | US | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
| US-20210205483-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-07-08 | — | — | US | disclosed |
| WO-2021068051-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-04-15 | — | — | WO | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KDM4E 2595/4885TDP1 4781/4885ALOX15 4708/4885 |
| US-11395857-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | MC1R, MC5R, MC3R | KDM4E 4242/4885TDP1 3150/4885ALOX15 3121/4885 |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | KDM4E 4312/4885TDP1 4305/4885ALOX15 3749/4885 |
| US-20210205483-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | MC1R, MC5R, MC3R | KDM4E 4278/4885TDP1 3144/4885ALOX15 3061/4885 |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | KDM4E 3809/4885TDP1 2049/4885ALOX15 4305/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | KDM4E 4511/4885TDP1 3249/4885ALOX15 4535/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KDM4E 2595/4885TDP1 4781/4885ALOX15 4708/4885 |
| US-20220040340-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | MC1R, MC3R, MC5R | KDM4E 4274/4885TDP1 2870/4885ALOX15 3106/4885 |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY1R, GIPR | KDM4E 3926/4885TDP1 872/4885ALOX15 2790/4885 |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | KLK3, FOLH1, HRH3 | KDM4E 1426/4885TDP1 3091/4885ALOX15 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.